Current perspectives on the contribution of inhaled corticosteroids to an increased risk for diabetes onset and progression in patients with chronic obstructive pulmonary disease

• Verfasst von: Herth, Felix [VerfasserIn]
• Verfasst von: Bramlage, Peter [VerfasserIn]
• Verfasst von: Müller-Wieland, Dirk [VerfasserIn]
• Titel: Current perspectives on the contribution of inhaled corticosteroids to an increased risk for diabetes onset and progression in patients with chronic obstructive pulmonary disease
• Verf.angabe: Felix J F. Herth, Peter Bramlage, Dirk Müller-Wieland
• Jahr: 2015
• Jahr des Originals: 2014
• Umfang: 10 S.
• Fussnoten: Published online: November 27, 2014 ; Gesehen am 27.08.2020
• Titel Quelle: Enthalten in: Respiration
• Ort Quelle: Basel : Karger, 1944
• Jahr Quelle: 2015
• Band/Heft Quelle: 89(2015), 1, Seite 66-75
• ISSN Quelle: 1423-0356
• DOI: doi:10.1159/000368371
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1727902009

Abstract

Recent studies have suggested that inhaled corticosteroids (ICS) play a role in the development of hyperglycemia and type-2 diabetes in patients with chronic obstructive pulmonary disease (COPD). Nevertheless, this corticosteroid-associated adverse effect remains controversial. Moreover, the pharmacokinetic properties and patient characteristics that might contribute to an increased risk for diabetes upon ICS exposure have not been thoroughly investigated. In the present review, we critically discuss current evidence regarding the relationship between ICS therapy in COPD patients and an increased risk for the incidence and progression of type-2 diabetes. In addition, we address therapeutic conditions, clinical implications, and future perspectives related to this potentially important ICS-associated adverse effect in COPD patients.